FDA approves Sanofi's Infilbray for neurological symptoms of Gaucher disease type 3
SNY•The FDA approved Sanofi's Infilbray (venglustat) as the first treatment for neurological manifestations of Gaucher disease type 3. The once-daily oral drug is indicated for adults and children weighing at least 15 kg; reviews remain underway in the European Union, Japan and other jurisdictions.
1. FDA approval
The FDA approved Sanofi's Infilbray (venglustat) as the first treatment for neurological manifestations of Gaucher disease type 3. The once-daily oral drug is indicated for adults and pediatric patients weighing at least 15 kg.
2. Other reviews underway
Regulatory reviews remain underway in the European Union, Japan and other jurisdictions.




